Sept 27 (Reuters) - Savara Inc :
* SAVARA ANNOUNCES EXPANDED ACCESS PROGRAM (EAP) FOR MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) FOR PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)
* SAVARA : SAVARA EARLY ACCESS ACCEPTING REQUESTS FROM PATIENTS IN SELECT COUNTRIES IN N.AMERICA & EUROPE, PLANS TO EXPAND THROUGH 2026
* SAVARA INC: PLANS TO COMPLETE SUBMISSION OF A BLA TO FDA FOR MOLGRAMOSTIM IN APAP IN H1 OF 2025
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。